Valuation
- Market cap
- 2,228,000
- Revenue TTM
- $0
- Net income TTM
- $-8,880,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.62
Trading
- Volume
- 245,100
- Avg volume
- 1,849,906
- Day's range
- $2.46 – $2.69
- Shares out
- 888,000
- Stochastic %K
- 16%
- Beta
- 1.80
- Analysts
- Strong Buy
- Price target
- $3.50
Company profile
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it...
Show more
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 888 276 6888
- Website
- https://valionbio.com
- Address
- 1305 E. Houston Street, Suite 311, Building 1, San Antonio, United States
Latest news
No headlines yet.
